Synapse - Ashley Regazzi

Results (93)

Relationship among DNA damage response gene alterations, molecular subtypes, and survival outcomes in patients with metastatic bladder cancer treated on CALGB 90601

Journal Article

Iyer, G.; Choi, W.; Luo, B.; Carvalho, F.; Hanlon, T.; Reis, H.; Guercio, B. J.; Fong, M.; Mountain, J.; Feng, M.; more...
JCO Precision Oncology (2025)

Fulltext@MSK | Save

Cutaneous toxicity and clinical outcomes with enfortumab vedotin and pembrolizumab in patients with locally advanced or metastatic urothelial carcinoma

Meeting Abstract

Arbuiso, A.; Sternschuss, M.; Whiting, K.; Gupta, A.; Huttenlocher Bent, E.; Alvarez, N.; Regazzi, A. M.; Liang, S.; Ahmed, F.; Akin, O.; more...
Journal of Clinical Oncology (2025)

Fulltext@MSK | Save

Treatment patterns and clinical outcomes with platinum-based chemotherapy after enfortumab vedotin and pembrolizumab in patients with metastatic urothelial carcinoma

Meeting Abstract

Sternschuss, M.; Whiting, K.; Arbuiso, A.; Gupta, A.; Bent, E. H.; Alvarez, N.; Regazzi, A. M.; Liang, S.; Ahmed, F.; Akin, O.; more...
Journal of Clinical Oncology (2025)

Fulltext@MSK | Save

Quality of informed consent via telemedicine compared with in-person for clinical cancer research

Journal Article

Sternschuss, M.; Lattanzi, M.; Vertosick, E.; Austria, M.; Martin, S.; Regazzi, A.; Buckely, M. T.; Lengfellner, J.; Riely, G. J.; Solit, D. B.; more...
JCO Oncology Practice (2025)

Fulltext@MSK | Save

A novel predictive model using changes in clinical and serum biomarkers and automated quantitative imaging for mCRPC patients treated with AR-directed therapy

Meeting Abstract

Morris, M. J.; Flynn, J.; Zhao, B.; Anand, A.; Sjöstrand, K.; Larson, S. M.; Scher, H. I.; Regazzi, A. M.; Borzillo, G. V.; Park, A.; more...
Journal of Clinical Oncology (2025)

Fulltext@MSK | Save

Characterizing the immune effects of enfortumab vedotin (EV) on peripheral blood mononuclear cells (PBMCs) in metastatic urothelial cancer patients (mUC)

Meeting Abstract

Gupta, A.; Sevilla, C.; Pihlstrom, N. L.; Liang, S.; Regazzi, A. M.; McCoy, A. S.; Maher, C. A.; Wong, P.; Ahmed, F.; Funt, S. A.; more...
Journal of Clinical Oncology (2025)

Fulltext@MSK | Save

Circulating tumor DNA and response to cisplatin-based chemotherapy in patients with metastatic urothelial carcinoma enrolled in CALGB 90601 (Alliance)

Journal Article

Guercio, B. J.; Whiting, K.; Shah, R. H.; Ballman, K. V.; Halabi, S.; Regazzi, A. M.; Milbank, J. H.; Bajorin, D. F.; Beltran, H.; Morris, M. J.; more...
European Urology Open Science (2025)

Fulltext@MSK | Save

DNA damage response alterations predict for neoadjuvant chemotherapy sensitivity in muscle-invasive bladder cancer: A correlative analysis of the SWOG S1314 trial

Journal Article

Iyer, G.; Tangen, C. M.; Sarfaty, M.; Regazzi, A. M.; Lee, I. L.; Fong, M.; Choi, W.; Dinney, C. P. N.; Flaig, T. W.; Thompson, I. M. Jr; more...
JCO Precision Oncology (2024)

Fulltext@MSK | Save

HER2 and PD-L1 immunohistochemistry (IHC) expression, and HER2 genomic alterations: Associations and clinical outcomes for advanced bladder cancer

Meeting Abstract

Aggen, D. H.; Shah, N. J.; Zheng, J.; Alam, S. M.; Balar, O.; Niederhausern, A.; Regazzi, A. M.; Ratna, N.; Funt, S. A.; Teo, M. Y.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

HER2 mutation and bladder cancer (BC): Prevalence and clinical outcomes

Meeting Abstract

Shah, N. J.; Aggen, D. H.; Zheng, J.; Niederhausern, A.; Alam, S. M.; Balar, O.; Bahadur, N.; Watson, A.; Regazzi, A. M.; Ratna, N.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save